Sotio Biotech is a clinical-stage immuno-oncology company based in Prague focused on advancing IL-15–based therapies and other oncology programs. Its lead asset is SOT101, an IL-15 superagonist that the company plans to move through two multi-indication phase 2 trials. Sotio also has three novel programs it intends to advance through phase 1: BOXR1030 (a CAR-T targeting GPC3), SOT102 (an ADC targeting Claudin 18.2), and an IL-15–based immunocytokine program to be tested with a PD-1 inhibitor. The company plans to use the new funding to progress these programs and SOT101’s trials through the end of 2023. Clinical development milestones and regulatory achievements are tied to the funding.

Total raised

$317M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2021